- Promotes Commercial Products at Major Cardiology Conferences -
- Convenes Opinion Leaders to Assist Product Development Efforts -
- Achieves Efficiencies and Conserves Cash by Consolidating R&D
VANCOUVER, Nov. 3 /PRNewswire-FirstCall/ - Neovasc Inc. (TSXV: NVC), a new specialty vascular device company, today reported on its commercial and product development progress, the consolidation and streamlining of its R&D operations, including the appointment of a noted interventional cardiologist as Medical Director, and the issuance of options.
Commercial and Development Progress
Neovasc recently showcased its commercially available products, including its innovative Metricath(R) intravascular measurement system and its Matrix(BP)(TM) biologic vascular patch for carotid procedures at several major cardiovascular medical conferences including New Cardiovascular Horizons (NCVH), Vascular Interventional Advances (VIVA), TransCatheter Therapeutics (TCT) and the Canadian Cardiovascular Congress (CCC). A number of key opinion leaders conducted scientific talks and seminars in support of Neovasc's products at these conferences and leading interventional cardiologists and vascular surgeons also participated in a series of new product development meetings sponsored by Neovasc.
Metricath was featured during NCVH "live case" seminars and in
symposiums at VIVA. A breakfast symposium at TCT highlighted the benefits
of Metricath with presentations by Dr. Jorge Saucedo, Oklahoma University
Medical Center, Dr. Rajesh Dave, Pinnacle Health Heart and Vascular
Institute at Harrisburg Hospital, Dr. Raed Aqel, Birmingham VA Medical
Center and Dr. David Allie, Cardiovascular Institute of the
South/Lafayette. Dr. Allie also presented an abstract for a Metricath study
in patients with IPA, a common type of artery disease, in which he
concludes that without Metricath, the "primary operat
|SOURCE Neovasc Inc.|
Copyright©2008 PR Newswire.
All rights reserved